Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Unicycive Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 1,413,381 shares, representing 5.3% of the outstanding common stock.
BlackRock has sole voting power over 1,391,049 shares and sole dispositive power over 1,413,381 shares, with no shared voting or dispositive power. Various underlying clients have economic interests in these shares, but no single client holds more than five percent of Unicycive’s outstanding common stock.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. director Sara Kenkare-Mitra reported an equity compensation award of 47,941 Restricted Stock Units on May 14, 2026. The RSUs are payable solely in common stock; 19,976 shares vest immediately and 3,995 vest monthly over seven months from June 1, 2026, contingent on continued service.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. director Sandeep Laumas received a grant of 47,941 restricted stock units on May 14, 2026, payable solely in common stock.
Of these, 19,976 RSUs vest upon grant and 3,995 vest monthly over seven months beginning June 1, 2026, subject to his continued service; post‑grant holdings total 47,941 RSUs.
Unicycive Therapeutics, Inc. amendment to a Schedule 13G/A reports shared beneficial ownership stakes held by Millennium-related entities and Integrated Core Strategies (US) LLC. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 271,456 shares (1.0%). Integrated Core Strategies (US) LLC reports 205,529 shares (0.8%). The filing includes a Joint Filing Agreement dated July 7, 2026 and discloses that the holdings are held by entities subject to voting and investment control by Millennium-affiliated managers.
Unicycive Therapeutics, Inc. reported an ending cash balance of approximately $61.4 million as of June 30, 2026. This figure is part of the company’s preliminary second-quarter results, which were prepared by management and have not been audited, reviewed, or compiled by its independent registered public accounting firm.
Unicycive Therapeutics, Inc. held its Annual Meeting of Stockholders on June 19, 2025, with 14,964,159 common shares represented, constituting a quorum. Stockholders elected three directors — Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare‑Mitra — to serve until the 2027 annual meeting or until successors are elected and qualified.
Support for the nominees ranged from 7,510,434 to 8,131,958 votes "for," with broker non‑votes exceeding 6.6 million for each. Stockholders also ratified the appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 14,667,242 votes in favor, 286,958 against, and 9,928 abstentions.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units (RSUs) payable in common stock. These RSUs are a form of equity compensation, not an open-market purchase or sale.
According to the award terms, 105,861 shares vest immediately upon grant. An additional 21,172 shares vest over 31 months beginning on June 1, 2026, contingent on Gupta’s continued service with the company. Following this grant, the Form 4/A shows Gupta holding 762,200 RSUs linked to common stock.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two new restricted stock unit (RSU) awards as equity compensation. On May 14, 2026, she was granted 42,100 RSUs and a separate 84,200 RSU annual award, each payable solely in common stock.
For the 42,100-unit RSU award, 11,694 shares vest immediately, with 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to her continued service. For the 84,200-unit annual RSU award, 17,542 shares vest upon grant and 3,508 vest monthly over 7 months starting the same date.